Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome

British Journal of Dermatology

Volumn 139, Issue 6, 1998, Pages 1026-1032

  Choquet Kastylevsky, Genevieve ^a,b   Intrator, L ^a   Chenal, C ^a   Bocquet, H ^a   Revuz, J ^a   Roujeau, J C ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; ANTIBIOTIC AGENT; CAPTOPRIL; CHLORMEZANONE; CLAVULANATE POTASSIUM; CLOXACILLIN; DIFEBARBAMATE; DIGOXIN; DIURETIC AGENT; FUROSEMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 5; LISINOPRIL; METRONIDAZOLE; MINOCYCLINE; NICARDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORAMIDOPYRINE; PEFLOXACIN; PHENOBARBITAL; PIROXICAM; TIEMONIUM IODIDE; VALPROIC ACID; ZALCITABINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ERUPTION; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; HUMAN; HYPERSENSITIVITY REACTION; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; SKIN DEFECT;

ADULT; AGED; AGED, 80 AND OVER; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-3; INTERLEUKIN-5; MALE; MIDDLE AGED;

EID: 0032420752     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02559.x     Document Type: Article

References (39)

1. Bocquet H, Bourgault-Villada I, Delfau-Larue M et al. Syndrome d'hypersensibilité à la dapsone. Clone T circulant transitoire. Ann Dermatol Venereol 1995; 122: 514-16.
2. Shear N, Spielberg SP. Anticonvulsivant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826-32.
3. Bonnetblanc JM. Drug hypersensitivity syndrome. Dermatology 1993; 187: 84-5.
4. Roujeau J-C, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
5. Parneix-Spake A, Bastuji-Garin S, Lobut J-B et al. Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol 1995; 131: 490-2.
6. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285-90.
7. Weller PF. The immunobiology of eosinophils. N Engl J Med 1991; 324: 1110-18.
8. Sehmi R, Wardlaw AJ, Cromwell O et al. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992; 79: 2952-9.
9. Koike T, Enokihara H, Arimura H et al. Serum concentrations of IL-5, GM-CSF, and IL-3 and the production by lymphocytes in various eosinophilia. Am J Hematol 1995; 50: 8-102.
10. Sedgwick JB, Quan SF, Calhoun WJ, Busse WW. Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: comparison with airway eosinophils. J Allergy Clin Immunol 1995; 96: 375-85.
11. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992; 79: 3101-9.
12. Takamoto M, Sugane K. Mechanisms of eosinophilia in Toxocara canis infected mice: in vitro production of interleukin 5 by lung cells of both normal and congenitally athymic nude mice. Parasite Immunol 1993; 15: 493-500.
13. Yamaguchi Y, Matsui T, Kasahara T et al. In vivo changes of hemopoietic progenitors and the expression of the inlerleukin 5 gene in eosinophilic mice infected with Toxocara canis. Exp Hematol 1990; 18: 1152-7.
14. Sur S, Gleich GJ, Swanson MC et al. Eosinophilic inflammation is associated with elevation of inlerleukin-5 in the airways of patients with spontaneous symptomatic asthma. J Allergy Clin Immunol 1995; 96: 661-8.
15. Till S, Li B, Durham S et al. Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopic asthmatics, and atopic and non-atopic controls. Eur J Immunol 1995; 25: 2727-31.
16. Ohnishi T, Sur S, Collins DS et al. Eosinophil survival activity identified as interleukin-5, as associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J Allergy Clin Immunol 1993; 92: 607-15.
17. Schrezenmeier H, Thome SD, Tewald F et al. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. Exp Hematol 1993; 21: 358-65.
18. Fang J, Viksman MY, Ebisawa M, Bochner BS. Increased circulating levels of interleukin-5 in a case of steroid-resistant hypereosinophilic syndrome with ileal involvement. J Allergy Clin Immunol 1994; 94: 129-31.
19. Takamizawa M, Iwata T, Watanabe K et al. Elevated production of interleukin-4 and interleukin-5 by T cells in a child with idiopathic hypereosinophilic syndrome. J Allergy Clin Immunol 1994; 93: 1076-8.
20. Mauri-Hellweg D, Bettens F, Mauri D et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155: 462-72.
21. Tsutsui H, Terano Y, Sakagami C et al. Drug-specific T cells derived from patients with drug-induced allergic hepatitis. J Immunol 1992; 149: 706-16.
22. Kan H, Ogata T, Taniyama A et al. Extraordinarily high eosinophilia and elevated serum interleukin-5 level observed in a patient infected with Paragonimus westermani. Pediatrics 1995; 96: 351-4.
23. Limaye AP, Ottesen EA, Kumaraswami V et al. Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis. J Infect Dis 1993; 167: 1396-400.
24. Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin-5 and granulocyte-macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992; 90: 1414-24.
25. Desreumaux P, Janin A, Colombel JF et al. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med 1992; 175: 293-6.
26. Collins PD, Marleau S, Griffiths-Johnson DA et al. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995; 182: 1169-74.
27. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Med 1996; 2: 449-56.
28. Venge J, Lampinen M, Haakansson L et al. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the astmatic lung. J Allergy Clin Immunol 1996; 97: 1110-15.
29. Hertl M, Merk HF. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995; 105: S95-8.
30. Shear N, Spielberg SP, Grant DM et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-84.
31. Wolkenstein P, Charue D, Laurent P et al. Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsivants. Arch Dermatol 1995; 131: 544-51.
32. Mikami C, Ochiai K, Tomioka H, Tanabe E. In vitro interleukin-5 (IL-5) production by peripheral blood mononuclear cells from patients with drug hypersensitivily. J Dermatol 1996; 23: 379-81.
33. Zanni MP, Mauri-Hellweg D, Brander C et al. Characterization of lidocaine-specific T cells. J Immunol 1997; 158: 1139-48.
34. Butterfield JH, Gleich GJ. Interferon-α treatment of six patients with the idiopathic hypersensitivity syndrome. Ann Intern Med 1994; 121: 648-53.
35. Fushimi M, Tokura Y, Sachi Y et al. Eosinophilic pustular folliculitis effectively treated with recombinant interferon-gamma: suppression of mRNA expression of interleukin 5 in peripheral blood mononuclear cells. Br J Dermatol 1996; 134: 766-72.
36. Devos R, Plaetinck G, Cornelis S et al. Interleukin-5 and its receptor: a drug target for eosinophilia associated with chronic allergic disease. J Leukoc Biol 1995; 57: 813-19.
37. Rothenberg ME. Mechanism of disease: eosinophilia. N Engl J Med 1998; 338: 1592-600.
38. Wolkenstein P, Chosidow O, Fléchet ML et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Derm 1996; 35: 234-6.
39. Vaillant L, Camenen I, Lorette G. Patch testing with carbamazepine: reinduction of an exfoliative dermatitis (letter). Arch Dermatol 1989; 125: 299.